{"id":796114,"date":"2022-06-06T14:05:06","date_gmt":"2022-06-06T12:05:06","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/"},"modified":"2023-07-11T15:15:20","modified_gmt":"2023-07-11T13:15:20","slug":"newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/","title":{"rendered":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals"},"content":{"rendered":"-- In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 --\n\n\n-- 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg\/dL, compared to 20% of patients treated with placebo --\n\n\n\u00a0-- New data further support opportunity for obicetrapib as an important potential option for high-risk patients, the majority of which are still above their LDL-c target goals due to the limitations of existing therapies --\n\nNAARDEN, Netherlands & MIAMI--(BUSINESS WIRE)--NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transfor
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

— In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 — — 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49624],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-796114","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-europe"],"acf":[],"yoast_head":"\nNewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez\" \/>\n<meta property=\"og:description\" content=\"-- In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 -- -- 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-06T12:05:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T13:15:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals\",\"datePublished\":\"2022-06-06T12:05:06+00:00\",\"dateModified\":\"2023-07-11T13:15:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\"},\"wordCount\":1162,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in Europe\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\",\"name\":\"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-06-06T12:05:06+00:00\",\"dateModified\":\"2023-07-11T13:15:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez","og_description":"-- In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 -- -- 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/","og_site_name":"BeBeez","article_published_time":"2022-06-06T12:05:06+00:00","article_modified_time":"2023-07-11T13:15:20+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals","datePublished":"2022-06-06T12:05:06+00:00","dateModified":"2023-07-11T13:15:20+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/"},"wordCount":1162,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in Europe"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/","name":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-06-06T12:05:06+00:00","dateModified":"2023-07-11T13:15:20+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/newamsterdam-pharma-shares-new-data-from-phase-2b-rose-study-showing-up-to-82-5-of-patients-with-dyslipidemia-attained-ldl-c-goals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/796114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=796114"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/796114\/revisions"}],"predecessor-version":[{"id":891622,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/796114\/revisions\/891622"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=796114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=796114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=796114"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=796114"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=796114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}